Tarenflurbil spraygel - MIKA Pharma

Drug Profile

Tarenflurbil spraygel - MIKA Pharma

Alternative Names: MIKA-tarenflurbil-spraygel; MK-50

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PAZ GmbH
  • Developer MIKA Pharma GmbH
  • Class Antidementias; Antineoplastics; Biphenyl compounds; Propionic acids; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase modulators; NF-kappa B inhibitors; Transcription factor AP-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Inflammation; Pain; Skin disorders

Most Recent Events

  • 02 May 2016 Chemical structure information added
  • 27 Apr 2016 Development is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top